The Biotech That Has Almost Doubled in 2017 With the Potential to Boom Even More Post author:Sam Post published:November 21, 2017 Post category:BioPharma Keith Speights, writing for The Motley Fool, notes one biotech that’s booming. Source: BioSpace You Might Also Like Debt-Ridden Valeant Nears Sale of Its $2 Billion Eye Care Biz Bausch & Lomb June 6, 2017 DURECT Stock Plunges as Pain Med Fails Phase III October 19, 2017 Celgene To Announce Second Quarter 2017 Results On July 27, 2017 July 4, 2017
